Ebola (EBO) and Marburg viruses are members of the family
fluid of a convalescent patient 61 days after onset of disease [7] , but it is unknown whether such patients can contribute to Filoviridae and cause severe hemorrhagic fever in human and nonhuman primates [1, 2] . Mortality rates of 80% -90% were filovirus transmission. During the 1995 EBO outbreak, patients admitted to Kikwit documented during the 1976 and 1995 outbreaks of EBO hemorrhagic fever (EHF) in the Democratic Republic of the Congo General Hospital, DRC, with a clinical diagnosis of EHF were isolated in a single hospital pavilion. Entrance to this pavilion (DRC) [3, 4] . The major routes of transmission during outbreaks appear to be contact with blood or infectious fluids from was restricted, and strict barrier-nursing techniques were implemented to prevent transmission to medical personnel and famdeceased patients and from persons in the acute phase of disease [1] . Since outbreaks usually occur in remote places where ily members caring for the patients [8, 9] . Patients who recovered from the disease were released from the isolation unit health care resources are scarce, only limited numbers of clinical samples have been available for analysis. Therefore, few into an adjacent building under more relaxed barrier-nursing conditions. Whether convalescent patients were shedding virus data exist concerning virus clearance, persistence, and shedding during the postclinical phase of the disease. There is evidence at the time of release was unknown. One of the objectives of this study was to determine whether EBO virus is still present suggesting that filoviruses can persist in convalescent patients. Marburg virus has been isolated from seminal fluid and from in body fluids of convalescent patients after clinical symptoms subside, and if so, what the duration of virus persistence is. the anterior chamber of the eye of convalescent patients recovering from hemorrhagic fever up to 80 days after onset of
Another aspect of the current study was to determine the genetic stability of EBO virus during the outbreak. Viruses disease [5, 6] . In addition, EBO virus was found in seminal with RNA genomes have the potential for rapid evolution due to the high error rate of their RNA polymerase [10] . As soon as clinical material from the outbreak was available, it was (20) skin, serum, blood skin, serum, blood skin, serum, blood clot (23) clot (27) clot ( skin, serum, blood skin, serum, blood skin, serum, blood clot (27) clot ( other was placed in a 1.5-mL microcentrifuge tube containing 500 mophilus (GeneAmp EZ rTth RNA PCR kit; Perkin-Elmer, Norwalk, CT). This enzyme performs both RT and DNA amplifimL of 4 M guanidine thiocyanate solution.
Additional samples included blood (obtained during the acute cation. Amplification was done using a thermocycler (model 9600; Perkin-Elmer) with a temperature profile of 50ЊC for 30 min (RT phase of disease) from 9 patients (figure 1). Among these samples were some from a suspected line of transmission that included at step) followed by 35 cycles at 94ЊC for 15 s and 50ЊC for 60 s and a final elongation step at 60ЊC for 10 min, for a total cycle least three human-to-human passages, some from 5 survivors and 4 deceased patients, and 2 from patients who provided multiple time of 2.4 h. Products were analyzed by electrophoresis on 2.5% agarose gels and visualized by ethidium bromide staining. We used samples through convalescence (figure 1). In addition, we also tested seminal fluid samples that were obtained from 5 convalestwo sets of primers that targeted the nucleocapsid protein (NP) and the GP genes of EBO virus. Primers REM2 and REM5, which cent patients (H-L, table 1) between 51 and 101 days after onset of disease as well as follow-up seminal fluid samples obtained target the NP gene of EBO virus, are described by Sanchez et al. [15] (in this issue). Two additional primers were designed for from 3 of these patients on days 700-707 after onset in April 1997 (table 1) .
amplification of the most variable region of the GP gene of EBO virus. The nt sequence of these primers and their 5 and 3 positions RNA extraction. All field work with potentially infectious material was performed using a HEPA filter-fitted positive air purifyrelative to the GP gene of 1976 strain of EBO-Z are as follows: GPZAI1201F Å 1201 5-ACAGTCAAGGAAGGGAAG-3 1218; ing respirator (Racal Systems, Frederick, MD) in a restricted-access laboratory of Kikwit General Hospital. Total RNA was GPZAI1485R Å 1502 5-GTTTTGGGGACTTGTTGT-3 1485. Direct sequencing of the amplimers was done by the dideoxy extracted using the acid-guanidine-phenol extraction procedure as previously described [14] . Tubes containing the aqueous phase chain termination method on a fluorescent-dye automated sequencer (Applied Biosystems, Foster City, CA), using the same (RNA in 4 M guanidine thiocyanate) were kept on ice for up to 2 weeks and then transported at room temperature (3 days) to CDC.
primers as used for RT-PCR. In some cases in which direct sequencing was not possible, PCR products were cloned using the RNA was precipitated from these samples by adding 1 vol of isopropanol, incubating overnight at 020ЊC, and centrifuging at TA cloning kit (InVitrogen, San Diego), and at least 3 clones of each sample were sequenced. Sequences were aligned and com-14,000 g for 20 min. RNA pellets were washed twice with 70% ethanol, dried under vacuum, and resuspended in 50 mL of diethyl pared using the Wisconsin Sequence Analysis Package (Genetics Computer Group, Madison, WI). pyrocarbonate-treated water. In the case of sera or blood, the RNaid kit (Bio 101, La Jolla, CA) was used instead of isopropanol Virus isolation. All procedures involving potentially infectious samples were done in a biosafety level 4 facility at CDC. Confluent precipitation. RNA samples were kept at 070ЊC until tested.
Amplification and sequencing of nucleic acids. A one-tube remonolayers of Vero E6 cells in T-25 flasks were inoculated with 0.05-0.1 mL of undiluted patient serum or plasma or with material verse transcription-polymerase chain reaction (RT-PCR) was performed using a thermostable DNA polymerase from Thermus therresuspended from swabs diluted in 1 mL of Hanks' balanced salt identical to one another and to the EBO-Z 1995 reference strain; however, they differed by 2 nt (1 amino acid change) from the EBO-Z 1976 reference strain ( figure 2A, B) .
Results
To test the genetic stability of the GP gene of EBO virus A total of 148 samples were obtained from 7 EHF patients among different patients during the course of the outbreak in in the isolation unit at Kikwit General Hospital on four samKikwit and also during persistence within the same patient, we pling dates between 2 and 13 July 1995 (table 1, patients selected 13 specimens from 9 patients for GP sequence analy-A -G). All patients were recovering and were at least 1 week sis. These specimens included the earliest (4 May 1995) and past their last EBO antigen -positive blood test. Several samlatest (19 June 1995) available samples from acutely infected ples of vaginal, rectal, and conjunctival swabs from patient F patients and samples from fatal and non-fatal cases (figure 1). were positive by RT-PCR for the presence of EBO virus NP Included were samples from a suspected line of transmission with at least three known human-to-human passages and an RNA for up to 33 days after onset of disease (table 1) . However, EBO virus isolated from seminal fluid of a patient 82 days inside cells, such as macrophages, or was bound to mucosal antibodies. after onset of disease (figure 1). The region of the GP gene sequenced was that known to be most divergent between An alternative explanation is that only viral RNA or viral nucleocapsids were present in these samples. The persistence of EBO-Z 1976 and EBO-Z 1995 [11] . Sequence analysis of 249 nt of this region found no nt differences among any of the viral RNA (presumably in the form of replicating intracellular nucleocapsids) in the absence of infectious virus has been resamples mentioned above (figure 3). As expected, 12 nt (6 amino acid) differences were observed between all the patients' ported in negative-strand RNA viruses, such as human respiratory syncytial virus and vesicular stomatitis virus [17 -19] . sequences and the EBO-Z 1976 virus ( figure 3A, B) .
However, in these systems, RNA was present in low copy numbers, and very sensitive nested PCR assays were necessary Discussion for detection. In this study, strong PCR products were obtained using single-tube, non-nested RT-PCR assays, suggesting that This study was done to better understand the potential secretion or excretion of EBO virus from infected patients during a large number of RNA molecules were present. Whether patient F could shed or transmit EBO virus during early convalescence. Viral RNA sequences were found in mucosal swab samples from a convalescent patient, indicating that this time or for how long virus was present in her mucosal membranes is unknown. Samples of seminal fluid were positive EBO virus may be capable of persisting in mucosal membranes for at least 33 days after onset of disease. The inability to for viral RNA in 4 of 5 convalescent patients tested as late as 101 days after onset of disease, and infectious virus was recovisolate virus in tissue culture from duplicates of the patient's mucosal swab samples could be due to loss of viability of the ered from a sample 82 days after onset of disease (see Rowe et al. [16] , in this issue). However, seminal fluid samples from virus during storage or transport from Kikwit to Atlanta or to the presence of virus at levels below the level of detection in 3 patients §700 days after onset of disease were RT-PCR negative even though earlier samples were positive. Taken totissue culture. It is also possible that virus was sequestered gether, these data suggest that these patients were probably [27 -29] . These viruses elicit strong host immunologic responses, and neutralizing antibodies are thought to be important shedding virus in the early convalescence phase following their release from the hospital but not at later times. Although no in driving their rapid evolution. In the case of EBO virus, this seems not to be the case, since nt changes were not detected secondary cases were associated with convalescent patients during this outbreak, our evidence for virus persistence in muin the most variable region of the GP gene even after 82 days of persistence within patient H. One possible explanation for cosal membranes and in seminal fluid should be carefully considered in the refinement of recommendations for release of this is the reported lack of a neutralizing antibody response in convalescent-phase sera from patients or experimental animals patients recovering from EHF. At a minimum, these precautions should include condom use by patients for at least 3 who survived infection with EBO virus [1] . Postclinical persistence of filoviruses certainly warrants further study. months after onset of disease.
The genetic stability of EBO virus was tested by sequencing the region of the GP gene previously found to be most divergent when the 1976 and 1995 strains of EBO-Z were compared [11] .
